Yunnan Botanee Bio-Technology GroupLTD Balance Sheet Health
Financial Health criteria checks 5/6
Yunnan Botanee Bio-Technology GroupLTD has a total shareholder equity of CN¥6.1B and total debt of CN¥592.5M, which brings its debt-to-equity ratio to 9.7%. Its total assets and total liabilities are CN¥7.7B and CN¥1.6B respectively. Yunnan Botanee Bio-Technology GroupLTD's EBIT is CN¥672.5M making its interest coverage ratio -7.5. It has cash and short-term investments of CN¥3.8B.
Key information
9.7%
Debt to equity ratio
CN¥592.46m
Debt
| Interest coverage ratio | -7.5x |
| Cash | CN¥3.77b |
| Equity | CN¥6.12b |
| Total liabilities | CN¥1.62b |
| Total assets | CN¥7.74b |
Recent financial health updates
Is Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) A Risky Investment?
Sep 25
Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Has A Pretty Healthy Balance Sheet
Feb 29Recent updates
Is Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Trading At A 39% Discount?
Oct 19The Market Lifts Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Shares 26% But It Can Do More
Sep 27Is Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) A Risky Investment?
Sep 25Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Will Pay A Smaller Dividend Than Last Year
Jun 03A Look At The Fair Value Of Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957)
May 24Yunnan Botanee Bio-Technology GroupLTD's (SZSE:300957) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 02Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Has A Pretty Healthy Balance Sheet
Feb 29Financial Position Analysis
Short Term Liabilities: 300957's short term assets (CN¥5.5B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 300957's short term assets (CN¥5.5B) exceed its long term liabilities (CN¥554.2M).
Debt to Equity History and Analysis
Debt Level: 300957 has more cash than its total debt.
Reducing Debt: 300957's debt to equity ratio has increased from 1.2% to 9.7% over the past 5 years.
Debt Coverage: 300957's debt is well covered by operating cash flow (78.8%).
Interest Coverage: 300957 earns more interest than it pays, so coverage of interest payments is not a concern.